2018

1. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

   Haematologica, Vol. 103, Núm. 8, pp. 1351-1358